TOP NEWS: AstraZeneca's Beyfortus wins EU approval for RSV in newborns

(Alliance News) - AstraZeneca PLC on Friday said its respiratory syncytial virus treatment ...

Alliance News 4 November, 2022 | 8:08AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - AstraZeneca PLC on Friday said its respiratory syncytial virus treatment Beyfortus, or nirsevimab, which it develops with Sanofi SA, has received EU approval for prevention of the virus in newborns and infants.

Cambridge, England-based AstraZeneca said: "Beyfortus is the first and only single-dose RSV passive immunisation for the broad infant population, including those born healthy, at term or preterm, or with specific health conditions."

The approval was based on results from the antibody's clinical development programme, including the Melody phase III trial.

The news follows a September recommendation for EU approval from the EU's European Medicine's Authority's Committee for Medicinal Products for Human Use.

RSV is a common contagious virus affecting the lungs and breathing passages, with no vaccines currently available for treatment.

London-based pharmaceutical firm GSK PLC in June said it is close to developing the world's first RSV vaccine. On Wednesday, GSK had said its RSV older adult vaccine candidate, which it estimates to be able to bring USD4 billion annually in sales, has been granted priority review by the US Food & Drug Administration.

By Tom Budszus; tombudszus@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
AstraZeneca PLC 10,436.00 GBX 0.13
GSK PLC 1,339.50 GBX 0.41
Sanofi SA 91.75 EUR -0.03

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures